Status:
NOT_YET_RECRUITING
Evaluating the Effect of N-Acetyl Cysteine and Alpha Lipoic Acid in Patients With Beta Thalassemia
Lead Sponsor:
Tanta University
Conditions:
Beta Thalassemia
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The current study is to investigate the potential roles of N-acetyl cysteine and Alpha-lipoic acid in patients with beta-thalassemia.
Detailed Description
Beta-thalassemia (β-thalassemia) is a hereditary blood disorder, which is characterized by a genetic disorder in the production of β-globin chains. β-thalassemia is inherited mainly by an autosomal re...
Eligibility Criteria
Inclusion
- Patients with beta-thalassemia who will receive conventional thalassemia management.
- Both genders.
- Age ≥ 18 years old.
Exclusion
- Patients with familial hypercholesterolemia or history of premature atherosclerosis.
- Patients with a prior history of significant cardiovascular diseases, such as coronary artery disease, myocardial infarction, or stroke.
- Patients with severe renal dysfunction.
- Patients with severe hepatic dysfunction.
- Patients with diabetes.
- Patients who will be non-compliant with the prescribed therapy.
- Patients with other hemoglobinopathies.
- Pregnant women.
- Obese patients.
- Patients who will receive antioxidant or anti-inflammatory medications.
- Patients with inflammatory diseases, such as Systemic lupus erythematous, rheumatoid arthritis and inflammatory bowel disease.
- Patients with oxidative stress related diseases, such as Alzheimer, Parkinson, COPD and cancer.
Key Trial Info
Start Date :
August 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2026
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT07157722
Start Date
August 30 2025
End Date
January 30 2026
Last Update
September 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Pharmacy - Tanta University
Tanta, Egypt, 31511